fda semaglutide compounding warning november 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Drugmakers battle pharmacies over compounded

That said, individual responses vary, and monitoring results helps ensure the combination works as intended

Regarding their protective effect against stroke, GLP-1RAs showed some heterogeneity in CVOTs, with the highest reduction in the risk of ischemic stroke reported for the long-acting GLP1-RA semaglutide at 28% [16] and no reduction for the short-acting lixisenatide [1]

Additionally, pancreatitis, though rare, typically presents with severe epigastric pain radiating to the back and requires immediate medical evaluation

Blood was collected from the tail vein up to 3 hours after gavage to measure TG levels and other metabolic parameters (4075 l per time point)